RxDoctor Payments Data

Stacey Malstrom, NP

Nurse Practitioner · Rome, GANPI 1003223934

Payments from drug & device makers

$2,311in general payments, 2019–2025

Across 85 payments — averaging $27.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$300
  • Kestra Medical Technology Services, Inc.$253
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$246
  • Merck$190
  • Abiomed$175
  • Abbott$163
  • plus $985 from 13 others

What the payments were for

  • Food & beverage$2,311100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,311 in reported general payments places this provider in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$24,005
Medicare patients
196
Services billed
222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$41,896
BrilintaTicagrelor22$18,468
JardianceEmpagliflozin19$18,267
FarxigaDapagliflozin Propanediol13$17,482
EntrestoSacubitril/Valsartan15$11,090
ClopidogrelClopidogrel Bisulfate65$717
Rosuvastatin Calcium46$564
Atorvastatin Calcium61$547
Metoprolol Succinate35$489
Ezetimibe16$354
Carvedilol39$334
Spironolactone28$237
Amlodipine Besylate26$151
Pravastatin Sodium13$134
Metoprolol Tartrate32$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$73$41,89636 claims
AstraZenecaBrilinta, Farxiga$80$35,95135 claims
Boehringer IngelheimJardiance$81$18,26719 claims
NovartisEntresto$300$11,09015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →